Esperion’s New Cholesterol-Busting Drug Hits The Market
ANN ARBOR—After years of development, Nexletol, the new cholesterol-reducer from Ann Arbor’s Esperion Therapeutics Inc., is now on the market and available in pharmacies in the United States. Nexletol uses a new mechanism of action to reduce low-density lipoprotein (LDL-C), the so-called bad cholesterol in the bloodstream, the cholesterol that can cause arterial blockages that